Abstract
Cannabinoid receptors (CB1 and CB2) and their endogenous ligands (endocannabinoids) have recently emerged as novel mediators of liver diseases. Endogenous activation of CB1 receptors promotes nonalcoholic fatty liver disease (NAFLD) and progression of liver fibrosis associated with chronic liver injury; in addition, CB1 receptors contribute to the pathogenesis of portal hypertension and cirrhotic cardiomyopathy. CB2 receptor-dependent effects are also increasingly characterized, including antifibrogenic effects and regulation of liver inflammation during ischemia-reperfusion and NAFLD. It is likely that the next few years will allow us to delineate whether molecules targeting CB1 and CB2 receptors are useful therapeutic agents for the treatment of chronic liver diseases.
Publisher
American Physiological Society
Subject
Physiology (medical),Gastroenterology,Hepatology,Physiology
Reference26 articles.
1. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis
2. Cannabinoid‐2 receptor mediates protection against hepatic ischemia/reperfusion injury
3. Deveaux V, Ichigotani Y, Teixeira-Clerc F, Manin S, Tran-Van-Nhieu J, Karsak M, Zimmer A, Mallat A, Lotersztajn S. CB2 receptor antagonism reduces diet-induced obesity, insulin resistance and hepatic steatosis. Hepatology 46 Suppl: 308A, 2007.
4. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats
5. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats
Cited by
94 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献